Cisplatin/epinephrine injectable gel - Novartis

Drug Profile

Cisplatin/epinephrine injectable gel - Novartis

Alternative Names: CDDP TI; Cisplatin therapeutic implant; cisplatin-e therapeutic implant; IntraDose-CDDP™; MPI-5010

Latest Information Update: 03 Nov 2009

Price : $50

At a glance

  • Originator Matrix Pharmaceutical
  • Developer Novartis
  • Class Antineoplastics; Catecholamines; Ethanolamines; Platinum complexes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer; Cancer metastases; Head and neck cancer; Liver cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Sarcoma; Solid tumours

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 15 May 2003 A study has been added to the Cancer therapeutic trials section
  • 13 Dec 2002 A study has been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top